Uncommon retinal vascular diseases

References

• Wong WT, Agro ́n E, Coleman HR, et al. Clinical characterization of retinal capillary hemangioblastomas in a large population of patients with von Hippel–Lindau disease. Ophthalmology. 2008;115(1):181–188.
   PubMed Web of Science ®Google Scholar
• American Academy of Ophthalmology, Ophthalmic Pathology and Intraocular Tumors. Basic and clinical science course 2010–2011.
   Google Scholar
• Kreusel K-M, Bechrakis NE, Krause L, et al. Retinal angiomatosis in von Hippel–Lindau disease: a longitudinal ophthalmologic study. Ophthalmology. 2006;113(8):1418–1424.
   PubMed Web of Science ®Google Scholar
• Heimann H, Damato B. Congenital vascular malformations of the retina and choroid. Eye. 2010;24(3):459–467.
   PubMed Web of Science ®Google Scholar
• Kreusel K-M, Bechrakis NE, Heinichen T, et al. Retinal angiomatosis and von Hippel–Lindau disease. Graefe’s Arch Clin Exp Ophthalmol. 2000;238(11):916–921.
   PubMed Web of Science ®Google Scholar
• Kreusel K-M, Bechrakis NE, Neumann HPH, et al. Solitary juxtapapillary capillary retinal angioma and von Hippel–Lindau disease. Can J Ophthalmol. 2007;42(2):251–255.
   PubMed Web of Science ®Google Scholar
• Singh AD, Nouri M, Shields CL, et al. Retinal capillary hemangioma: a comparison of sporadic cases and cases associated with von Hippel–Lindau disease. Ophthalmology. 2001;108:1907–1911.
   PubMed Web of Science ®Google Scholar
• Singh A, Shields J, Shields C. Solitary retinal capillary hemangioma: hereditary (von Hippel–Lindau disease) or nonhereditary? Arch Ophthalmol. 2001;119:232–234.
   PubMedGoogle Scholar
• Richard S, Chauveau D, Chrétien Y, et al. Renal lesions and pheochromocytoma in von Hippel–Lindau disease. Adv Nephrol Necker Hosp. 1994;23:1–27.
   PubMedGoogle Scholar
• Shields JA, Shields CL, Deglin E. Retinal capillary hemangioma in Marshall–Stickler syndrome. Am J Ophthalmol. 1997;124:120–122.
   PubMed Web of Science ®Google Scholar
• Maher ER, Yates JR, Harries R, et al. Clinical features and natural history of von Hippel–Lindau disease. Q J Med. 1990;77:1151–1163.
   PubMedGoogle Scholar
• Shields JA, Shields CL, editors. A textbook and atlas. Philadelphia (PA): WB Saunders Co; 1992.
   Google Scholar
• Heimann H, Jmor F, Damato B. Imaging of retinal and choroidal vascular tumours. Eye. 2013;27:208–216.
   PubMed Web of Science ®Google Scholar
• Turell ME, Singh AD. Vascular tumors of the retina and choroid: diagnosis and treatment. Middle East African J Ophthalmol. 2010;17(3):191–200.
   PubMedGoogle Scholar
• Shields CL, Materin MA, Shields J. Review of optical coherence tomography for intraocular tumors. Curr Opin Ophthalmol. 2005;16(3):141–154.
   PubMedGoogle Scholar
• Say EAT, Shah SU, Ferenczy S, et al. Optical coherence tomography of retinal and choroidal tumors. J Ophthalmol. 2012;2012:385058.
   PubMedGoogle Scholar
• Shields CL, Mashayekhi A, Luo CK, et al. Optical coherence tomography in children: analysis of 44 eyes with intraocular tumors and simulating conditions. J Pediatr Ophthalmol Strabismus. 2004;41(6):33.
   Web of Science ®Google Scholar
• Shanmugam PM, Ramanjulu R. Vascular tumors of the choroid and retina. Indian J Ophthalmol. 2015 Feb;63(2):133–140.
   PubMed Web of Science ®Google Scholar
• Singh AD. Intraocular vascular tumors. Saudi J Ophthalmol. 2007;21:1.
   Google Scholar
• Schmidt D, Natt E, Neumann HP. Long-term results of laser treatment for retinal angiomatosis in von Hippel–Lindau disease. Eur J Med Res. 2000;5:47–58.
   PubMedGoogle Scholar
• Singh AD, Nouri M, Shields CL, et al. Treatment of retinal capillary hemangioma. Ophthalmology. 2002;109:1799–1806.
   PubMed Web of Science ®Google Scholar
• Parmar DN, Mireskandari K, McHugh D. Transpupillary thermotherapy for retinal capillary hemangioma in von Hippel–Lindau disease. Ophthalmic Surg Lasers. 2000;31:334–336.
   PubMedGoogle Scholar
• Garcia-Arumı́ J, Sararols LH, Cavero L, et al. Therapeutic options for capillary papillary hemangiomas. Ophthalmology. 2000;107:48–54.
   PubMed Web of Science ®Google Scholar
• Raja D, Benz MS, Murray TG, et al. Salvage external beam radiotherapy of retinal capillary hemangiomas secondary to von Hippel–Lindau disease: visual and anatomic outcomes. Ophthalmology. 2004;111:150–153.
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth UM, Kusserow C, Barbazetto IA, et al. Benefits and complications of photodynamic therapy of papillary capillary hemangiomas. Ophthalmology. 2002;109:1256–1266.
   PubMed Web of Science ®Google Scholar
• Farah ME, Uno F, Höfling-Lima AL, et al. Transretinal feeder vessel ligature in von Hippel–Lindau disease. Eur J Ophthalmol. 2001;11:386–388.
   PubMed Web of Science ®Google Scholar
• Ach T, Thiemeyer D, Hoeh AE, et al. Intravitreal bevacizumab for retinal capillary haemangioma: longterm results. Acta Ophthalmol. 2010;88:e137–e138.
   PubMed Web of Science ®Google Scholar
• Coats G. Forms of retinal disease with massive exudation. Roy Lond Ophthal Hosp Rep. 1908;17(3):440–525.
   Google Scholar
• Shields JA, Shields CL, Honavar SG, et al. Classification and management of Coats disease: the 2000 proctor lecture. Am J Ophthalmol. 2001;131:572–583.
   PubMed Web of Science ®Google Scholar
• Senft SH, Hidayat AA, Cavender JC. Atypical presentation of Coats disease. Retina. 1994;14(1):36–38.
   PubMed Web of Science ®Google Scholar
• Cahill M, O’Keefe M, Acheson R, et al. Classification of the spectrum of Coats’ disease as subtypes of idiopathic retinal telangiectasis with exudation. Acta Ophthalmol Scand. 2001;79(6):596–602.
   PubMedGoogle Scholar
• Otani T, Yasuda K, Aizawa N, et al. Over 10 years follow-up of Coats’ disease in adulthood. Clin Ophthalmol. 2011;5:1729–1732.
   PubMedGoogle Scholar
• Smithen LM, Brown GC, Brucker AJ, et al. Coats’disease diagnosed in adulthood. Ophthalmology. 2005;112:1072–1078.
   PubMed Web of Science ®Google Scholar
• Beselga D, Campos A, Mendes S, et al. Refractory coats’ disease of adult onset. Case Rep Ophthalmol. 2012;3(1):118–122.
   PubMedGoogle Scholar
• Briggs TA, Abdel-Salam GM, Balicki M, et al. Cerebroretinal microangiopathy with calcifications and cysts (CRMCC). Am J Med Genet. 2008;146A:182–190.
   PubMed Web of Science ®Google Scholar
• Abouammoh MA, Al-Shibani SK, Alhawwas A, et al. Coats-like retinopathy in Joubert syndrome. J Aapos. 2016 Jun 30;20:372–374.
   PubMed Web of Science ®Google Scholar
• Stacey AW, Sparagna C, Borri M, et al. A 6-year-old boy with Cornelia de Lange syndrome and Coats disease: case report and review of the literature. J Aapos. 2015;19(5):474–478.
   PubMed Web of Science ®Google Scholar
• Morris B, Foot B, Mulvihill A. A population-based study of Coats disease in the United Kingdom I: epidemiology and clinical features at diagnosis. Eye. 2010;24(12):1797–1801.
   PubMed Web of Science ®Google Scholar
• Tripathi R, Ashton N. Electron microscopical study of Coat’s disease. Br J Ophthalmol. 1971;55:289–301.
   PubMed Web of Science ®Google Scholar
• Black GC, Perveen R, Bonshek R, et al. Coats’disease of the retina (unilateral retinal telangiectasis) caused by somatic mutation in the NDP gene: a role for norrin in retinal angiogenesis. Hum Mol Gnet. 1999;8:2031–2035.
   PubMed Web of Science ®Google Scholar
• Al-Qahtani AA, Almasaud JM, Ghazi NG. Clinical characteristics and treatment outcomes of coats disease in a Saudi Arabian population. Retina. 2015;35(10):2091–2099.
   PubMed Web of Science ®Google Scholar
• Shields JA, Shields CL, Honavar SG, et al. Clinical variations and complications of Coats disease in 150 cases: the 2000 Sanford Gifford memorial lecture. Am J Ophthalmol. 2001;131(5):561–571.
   PubMed Web of Science ®Google Scholar
• Stacey AW, Borri M, Francesco SD, et al. A case of anterior chamber cholesterolosis due to Coats’ disease and a review of reported cases. Open Ophthalmol J. 2016;10:27–32.
   PubMedGoogle Scholar
• Shields JA, Eagle RC Jr, Fammartino J, et al. Coats’ disease as a cause of anterior chamber cholesterolosis. Arch Ophthalmol. 1995;113(8):975–977.
   PubMedGoogle Scholar
• Gupta N, Beri S, D’souza P. Cholesterolosis bulbi of the anterior chamber in coats disease. J Pediatr Ophthalmol Strabismus. 2009. DOI:10.3928/01913913-20090616-04
   Google Scholar
• Patel AK, Murphy M, Shields CL. Picture of the month: anterior chamber cholesterolosis in Coats disease. Arch Pediatr Adolesc Med. 2011;165(12):1131–1132.
   PubMedGoogle Scholar
• Yannuzzi NA, Tzu JH, Ko AC, et al. Ocular findings and treatment of a young boy with Coats’ plus. Ophthalmic Surg Lasers Imaging Retina. 2014;45(5):462–465.
   PubMed Web of Science ®Google Scholar
• Suzani M, Moore AT. Intraoperative fluorescein angiography-guided treatment in children with early Coats’ disease. Ophthalmology. 2015;122(6):1195–1202.
   PubMed Web of Science ®Google Scholar
• Tarkkanen A, Laatikainen L. Coat’s disease: clinical, angiographic, histopathological findings and clinical management. Br J Ophthalmol. 1983;67:766–776.
   PubMed Web of Science ®Google Scholar
• Stanga PE, Papayannis A, Tsamis E, et al. Swept-source optical coherence tomography angiography of paediatric macular diseases. Dev Ophthalmol. 2016;56:166–173.
   PubMedGoogle Scholar
• Yang Q, Wei W, Shi X, et al. Successful use of intravitreal ranibizumab injection and combined treatment in the management of Coats’ disease. Acta Ophthalmol. 2016;94(4):401–406.
   PubMed Web of Science ®Google Scholar
• Reichstein DA, Recchia FM. Coats disease and exudative retinopathy. Int Ophthalmol Clin. 2011;51:93–112.
   PubMedGoogle Scholar
• Shields CL, Uysal Y, Benevides R, et al. Retinoblastoma in an eye with features of Coats’ disease. J Pediatr Ophthalmol Strabismus. 2006;43:313–315.
   PubMed Web of Science ®Google Scholar
• Shields CL, Ghassemi F, Tuncer S, et al. Clinical spectrum of diffuse infiltrating retinoblastoma in 34 consecutive eyes. Ophthalmology. 2008;115:2253–2258.
   PubMed Web of Science ®Google Scholar
• Mulvihill A, Morris B. A population-based study of Coats disease in the United Kingdom II. Investigation, treatment, and outcomes. Eye. 2010;24:1802–1807.
   PubMed Web of Science ®Google Scholar
• Spitznas M, Joussen F, Wessing A. Treatment of Coats’ disease with photocoagulation. Albrecht von Graefes Arch Klin Exp Ophthalmol. 1976;199:31–37.
   PubMedGoogle Scholar
• Haut J, van Effenterre G, Marre JM, et al. Treatment of Coats’ disease with argon laser photocoagulation. Bull Soc Ophtalmol Fr. 1979;79:463–465.
   PubMedGoogle Scholar
• Ridley ME, Shields JA, Brown GC, et al. Coats’ disease. Evaluation of management. Ophthalmology. 1982;89:1381–1387.
   PubMed Web of Science ®Google Scholar
• Sneed SR, Blodi CF, Pulido JS. Treatment of Coats’ disease with the binocular indirect argon laser photocoagulator. Arch Ophthalmol. 1989;107:789–790.
   PubMedGoogle Scholar
• Kıratlı H, Eldem B. Management of moderate to advanced Coats’ disease. Ophthalmologica. 1998;212:19–22.
   PubMed Web of Science ®Google Scholar
• Nucci P, Bandello F, Serafino M, et al. Selective photocoagulation in Coats’ disease: ten-year follow-up. Eur J Ophthalmol. 2002;12:501–505.
   PubMed Web of Science ®Google Scholar
• Couvillion SS, Margolis R, Mavrofjides E, et al. Laser treatment of Coats’ disease. J Pediatr Ophthalmol Strabismus. 2005;42:367–368.
   PubMed Web of Science ®Google Scholar
• Schefler AC, Berrocal AM, Murray TG. Advanced Coats’ disease. Management with repetitive aggressive laser ablation therapy. Retina. 2008;28:S38–S41.
   PubMed Web of Science ®Google Scholar
• Mrejen S, Metge F, Denion E, et al. Management of retinal detachment in Coats disease. Study of 15 cases. Retina. 2008;28:26–32.
   Web of Science ®Google Scholar
• Haut J, Zeghal M, Limon S. Cryotherapy of Eales’ disease and Coats’ disease. Bull Soc Ophtalmol Fr. 1970;70:182–184.
   PubMedGoogle Scholar
• Bergstrom CS, Hubbard GB 3rd. Combination intravitreal triamcinolone injection and cryotherapy for exudative retinal detachments in severe Coats disease. Retina. 2008;28:S33–S37.
   PubMed Web of Science ®Google Scholar
• Kranias G, Krebs TP. Advanced Coats’ disease successfully managed with vitreo-retinal surgery. Eye. 2002;16:500–501.
   PubMed Web of Science ®Google Scholar
• Ozdamar Y, Berker N, Batman C, et al. Vitreoretinal surgery in advanced Coats disease. Retinal Cases Brief Rep. 2009;3:57–59.
   PubMedGoogle Scholar
• Venkatesh P, Mandal S, Garg S. Management of Coats disease with bevacizumab in 2 patients. Can J Ophthalmol. 2008;43:245–246.
   PubMed Web of Science ®Google Scholar
• Othman IS, Moussa M, Bouhaimed M. Management of lipid exudates in Coats disease by adjuvant intravitreal triamcinolone: effects and complications. Br J Ophthalmol. 2010;94:606–610.
   PubMed Web of Science ®Google Scholar
• Sein J, Tzu JH, Murray TG, et al. Treatment of Coats’ disease with combination therapy of intravitreal bevacizumab, laser photocoagulation, and sub-tenon corticosteroids. Ophthalmic Surg Lasers Imaging Retina. 2016;47(5):443–449.
   PubMed Web of Science ®Google Scholar
• Lin C-J, Chen S-N, Hwang J-F, et al. Combination treatment of pediatric Coats’ disease: a bicenter study in Taiwan. J Pediatr Ophthalmol Strabismus. 2013;50(6):356–362.
   PubMed Web of Science ®Google Scholar
• Ramasubramanian A, Shields CL. Bevacizumab for Coats’ disease with exudative retinal detachment and risk of vitreoretinal traction. Br J Ophthalmol. 2012;96(3):356–359.
   PubMed Web of Science ®Google Scholar
• Bhat V, D’Souza P, Shah PK, et al. Risk of tractional retinal detachment following intravitreal bevacizumab along with subretinal fluid drainage and cryotherapy for stage 3b Coats’ disease. Middle East Afr J Ophthalmol. 2016;23(2):208–211.
   PubMed Web of Science ®Google Scholar
• Budning AS, Heon E, Gallie BL. Visual prognosis of Coats’ disease. J Aapos. 1998;2:356–359.
   PubMedGoogle Scholar
• Shienbaum G, Tasman WS. Coats disease: a lifetime disease. Retina. 2006;26(4):422–424.
   PubMed Web of Science ®Google Scholar
• Pérez-Campagne E, Wolfensberger TJ. Reemergence of dormant Coats disease after 30 years. Eur J Ophthalmol. 2012;22(3):509–512.
   PubMed Web of Science ®Google Scholar
• Gass JD, Oyakawa RT. Idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol. 1982;100:769–780.
   PubMedGoogle Scholar
• Nowilaty SR, Al-Shamsi HN, Al-Khars W. Idiopathic juxtafoveolar retinal telangiectasis: a current review. Middle East Afr J Ophthalmol. 2010;17(3):224–241.
   PubMedGoogle Scholar
• Gass JD, Blodi BA. Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology. 1993;100:1536–1546.
   PubMed Web of Science ®Google Scholar
• Yannuzzi LA, Bardal AM, Freund KB, et al. Idiopathic macular telangiectasia. Arch Ophthalmol. 2006;124:450–460.
   PubMedGoogle Scholar
• Clemons TE, Gillies MC, Chew EY, et al.; for the MacTel Research Group. The national eye institute visual function questionnaire in the macular telangiectasia (MacTel) project. Invest Ophthalmol Vis Sci. 2008;49:4340–4346.
   PubMed Web of Science ®Google Scholar
• Jacob J, Krivosic V, Paques M, et al. Cone density loss on adaptive optics in early macular telangiectasia type 2. Retina. 2016;36(3):545–551.
   PubMed Web of Science ®Google Scholar
• Paunescu LA, Ko TH, Duker JS, et al. Idiopathic juxtafoveal retinal telangiectasis: new findings by ultrahigh-resolution optical coherence tomography. Ophthalmology. 2006;113:48–57.
   PubMed Web of Science ®Google Scholar
• Moisseiev J, Lewis H, Bartov E, et al. Superficial retinal refractile deposits in juxtafoveal telangiectasis. Am J Ophthalmol. 1990;109:604–605.
   PubMed Web of Science ®Google Scholar
• Wong WT, Forooghian F, Majumdar Z, et al. Fundus autofluorescence in type 2 idiopathic macular telangiectasia: correlation with optical coherence tomography and microperimetry. Am J Ophthalmol. 2009;148:573–583.
   PubMed Web of Science ®Google Scholar
• Cohen SM, Cohen ML, El-Jabali F, et al. Optical coherence tomography findings in nonproliferative group 2a idiopathic juxtafoveal retinal telangiectasis. Retina. 2007;27:59–66.
   PubMed Web of Science ®Google Scholar
• Gaudric A, Ducos de Lahitte G, Cohen SY, et al. Optical coherence tomography in group 2A idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol. 2006;124:1410–1419.
   PubMedGoogle Scholar
• Spaide RF, Klancnik JM Jr, Cooney MJ. Retinal vascular layers in macular telangiectasia type 2 imaged by optical coherence tomographic angiography. JAMA Ophthalmol. 2015 Jan;133(1):66–73.
   PubMed Web of Science ®Google Scholar
• Gaudric A, Krivosic V, Tadayoni R. Outer retina capillary invasion and ellipsoid zone loss in macular telangiectasia type 2 imaged by optical coherence tomography angiography. Retina. 2015 Nov;35(11):2300–2306.
   PubMed Web of Science ®Google Scholar
• Gass JD. Histopathologic study of presumed parafoveal telangiectasis. Retina. 2000;20:226–227.
   PubMed Web of Science ®Google Scholar
• Green WR, Quigley HA, De la Cruz Z, et al. Parafoveal retinal telangiectasis.light and electron microscopy studies. Trans Ophthalmol Soc U K. 1980;100:162–170.
   PubMedGoogle Scholar
• Powner MB, Gillies MC, Tretiach M, et al. Perifoveal müller cell depletion in a case of macular telangiectasia type 2. Ophthalmology. 2010 Dec;117(12):2407–2416.
   PubMed Web of Science ®Google Scholar
• Spaide RF, Klancnik JM Jr, Cooney MJ, et al. Volume-rendering optical coherence tomography angiography of macular telangiectasia type 2. Ophthalmology. 2015 Nov;122(11):2261–2269.
   PubMed Web of Science ®Google Scholar
• Charbel Issa P, Scholl HP, Gaudric A, et al. Macular full-thickness and lamellar holes in association with type 2 idiopathic macular telangiectasia. Eye (Lond). 2009 Feb;23(2):435–441.
   PubMed Web of Science ®Google Scholar
• Gualino V, Cohen SY, Delyfer M-N, et al. Optical coherence tomography findings in tamoxifen retinopathy. Am J Ophthalmol. 2005 Oct;140(4):757–758.
   PubMed Web of Science ®Google Scholar
• Pitkänen L, Tommila P, Kaarniranta K, et al. Retinal arterial macroaneurysms. Acta Ophthalmol. 2014;92:101–104.
   PubMed Web of Science ®Google Scholar
• Campbell FB. Coats’ disease and congenital vascular retinopathy. Trans Am Ophthalmol Soc. 1976;74:366–424.
   Google Scholar
• Robertson DM. Macroaneurysms of the retinal arteries. Ophthalmology (Rochester). 1973;77:55–67.
   Google Scholar
• Moosavi RA, Fong KC, Chopdar A. Retinal artery nacroaneurysms: clinical and fluorescein angiographic features in 34 patients. Eye (Lond). 2006;20:1011–1020.
   PubMed Web of Science ®Google Scholar
• Abdel-Khalek MN, Richardson J. Retinal macroaneursysm: natural history and guidelines for treatment. Br J Ophthalmol. 1986;70:2–11.
   PubMed Web of Science ®Google Scholar
• Nadel AJ, Gupta KK. Macroaneurysms of the retinal arteries. Arch Ophthalmol. 1976;94:1092–1096.
   PubMedGoogle Scholar
• Cousins SW, Flynn HW Jr, Clarkson JG. Macroaneurysms associated with retinal branch vein occlusion. Am J Ophthalmol. 1990;109:567–570.
   PubMed Web of Science ®Google Scholar
• Dhindsa HS, Abboud EB. Familial retinal arterial macroaneurysms. Retina. 2002;22:607–615.
   PubMed Web of Science ®Google Scholar
• Bandello F, Corcóstegui B. ESASO course series. Vol. 1. Medical retina. Suisse: Karger; 2012.
   Google Scholar
• Meyer JC, Ahmad BU, Blinder KJ, et al. Laser therapy versus observation for symptomatic retinal artery macroaneurysms. Greafes Arch Clin Exp Ophthalmol. 2015;253:537–541.
   PubMed Web of Science ®Google Scholar
• Chanana B, Azad RV. Intravitreal bevacizumab for macular edema secondary to retinal macroaneurysm. Eye. 2009;23:491–493.
   Web of Science ®Google Scholar
• Golan S, Goldenberg D, Goldstein M. Long-term follow-up of intravitreal bevacizumab in retinal arterial macroaneurysm: a case report. Case Rep Ophthalmol. 2011;2:387–391.
   PubMedGoogle Scholar
• Wenkstern AR, Petersen H. Intravitreal ranibizumab in retinal macroaneurysm. Graefes Arch Clin Ophthalmol. 2010;248:1667–1670.
   PubMed Web of Science ®Google Scholar
• Gallego-Pinazo R, Martinez-Castillo S, Arévalo JF, et al. Ranibizumab for retinal arterial macroaneurysm. Graefes Arch Clin Exp Ophthalmol. 2011;249:1267–1268.
   PubMed Web of Science ®Google Scholar
• Erol MK, Dogan B, Coban DT. Intravitreal ranibuzumav theraphy for retinal arterial macroaneurysm. Int J Clin Exp Med. 2015 Jul 15;8(7):11572–11578.
   PubMed Web of Science ®Google Scholar
• Pichi F, Morara M, Torrazza C, et al. Intravitreal bevacizumab for macular complications from retinal arterial macroaneurysms. Am J Ophthalmol. 2013;155:287–294.
   PubMed Web of Science ®Google Scholar
• Menezes Rui C, CarvalhoTeixeira R, Teixeira C, et al. Foveal exudative macroaneurysm treated with intravitreal ranibizumab. Case Rep Ophthalmol. 2015;6:170–175.
   PubMedGoogle Scholar
• Mansour AM, Walsh JB, Henkind P. Arteriovenous anastomoses of the retina. Ophthalmology. 1987;94:35–40.
   PubMed Web of Science ®Google Scholar
• Schmidt D, Pache M, Schumacher M. The congenital unilateral retinocephalic vascular malformation syndrome (Bonnet-Dechaume-Blanc syndrome or Wyburn-Mason syndrome): review of the literature. Surv Ophthalmol. 2008;53:227–249.
   PubMed Web of Science ®Google Scholar
• Archer DB, Deutman A, Ernest JT, et al. Arteriovenous communications of the retina. Am J Ophthalmol. 1973;75:224–241.
   PubMed Web of Science ®Google Scholar
• Bhattacharya JJ, Luo CB, Suh DC, et al. Wyburn-Mason or Bonnet-Dechaume-Blanc as cerebrofacial arteriovenous metameric syndromes (CAMS). A new concept and a new classification. Interv Neuroradiol. 2001;7:5–17.
   PubMed Web of Science ®Google Scholar
• Iwata A, Mitamura Y, Niki M, et al. Binarization of enhanced depth imaging optical coherence tomographic images of an eye with Wyburn-Mason syndrome: a case report. BMC Ophthalmol. 2015;15:19.
   PubMed Web of Science ®Google Scholar
• Sharma P, Sridhar J, Rayess N, et al. Optical coherence tomography angiography (OCT-A) of a type 2 retinal arteriovenous alformation. Can J Ophthalmol. 2015;50:e93–e96.
   Web of Science ®Google Scholar
• Kushner MS, Jampol LM, Haller JA. Cavernous hemangioma of the optic nerve. Retina. 1994;14:359–361.
   PubMed Web of Science ®Google Scholar
• Webster AR, Maher ER, Bird AC, et al. A clinical and molecular genetic analysis of solitary ocular angioma. Ophthalmology. 1999;106(3):623–629.
   PubMed Web of Science ®Google Scholar
• Nikoskelainen E, Hoyt WF, Nummelin K, et al. Fundus findings in Leber’s hereditary optic neuroretinopathy III. Fluorescein angiographic studies. Arch Ophthalmol. 1984;102:981.
   PubMedGoogle Scholar
• Winter E, Elsås T, Austeng D. Anti-VEGF treating macular oedema caused by retinal arteriovenous malformation – a case report. Acta Ophthalmol. 2014 Mar;92(2):192–193.
   PubMed Web of Science ®Google Scholar
• Papageorgiou KI, Ghazi-Nouri SM, Andreou PS. Vitreous and subretinal haemorrhage: an unusual complication of retinal racemose haemangioma. Clin Experiment Ophthalmol. 2006 Mar;34(2):176–177.
   PubMed Web of Science ®Google Scholar
• Soliman W, Haamann P, Larsen M. Exudation response to photocoagulation and spontaneous remission in a case of bilateral racemose haemangioma. Acta Ophthalmol Scand. 2006 Jun;84(3):429–431.
   PubMedGoogle Scholar
• Chuang LH, Wang NK, Chen YP, et al. Mature vessel occlusion after anti-VEGF treatment in a retinal arteriovenous malformation. BMC Ophthalmol. 2013 Oct 21;13:60.
   PubMed Web of Science ®Google Scholar
• Gilbert C, Fielder A, Gordillo L, et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics. 2005;115:e518–e525.
   PubMed Web of Science ®Google Scholar
• Martin CR. Preventing bioenergetic failure in the preterm infant. Arch Dis Child Fetal Neonatal Ed. 2016;101:F99–F101.
   PubMed Web of Science ®Google Scholar
• Hellström A, Ley D, Hansen-Pupp I, et al. New insights into the development of retinopathy of prematurity-importance of early weight gain. Acta Paediatr. 2010;99:502–508.
   PubMed Web of Science ®Google Scholar
• Zin A, Gole GA. Retinopathy of prematurity-incidence today. Clin Perinatol. 2013;40:185–200.
   PubMed Web of Science ®Google Scholar
• Hellström A, Smith LE, Dammann O. Retinopathy of prematurity. Lancet. 2013;382(9902):1445–1457.
   PubMed Web of Science ®Google Scholar
• Chan-Ling T, Gock B, Stone J. The effect of oxygen on vasoformative cell division. Evidence that ‘physiological hypoxia’ is the stimulus for normal retinal vasculogenesis. Invest Ophthalmol Vis Sci. 1995;36:1201–1214.
   PubMed Web of Science ®Google Scholar
• International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol. 2005;123:991–999.
   PubMed Web of Science ®Google Scholar
• Good WV, Hardy RJ. The multicenter study of early treatment for retinopathy of prematurity (ETROP). Ophthalmology. 2001;108:1013–1014.
   PubMed Web of Science ®Google Scholar
• Azuma N, Ishikawa K, Hama Y, et al. Early vitreous surgery for aggressive posterior retinopathy of prematurity. Am J Ophthalmol. 2006;142:636–643.
   PubMed Web of Science ®Google Scholar
• Vinekar A, Trese MT, Capone A Jr. Evolution of retinal detachment in posterior retinopathy of prematurity: impact on treatment approach. Am J Ophthalmol. 2008;145:548–555.
   PubMed Web of Science ®Google Scholar
• Azad R, Chandra P. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol. 2007;55:319. author reply 20.
   PubMedGoogle Scholar
• Chung EJ, Kim JH, Ahn HS, et al. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2007;245:1727–1730.
   PubMed Web of Science ®Google Scholar
• Lalwani GA, Berrocal AM, Murray TG, et al. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina. 2008;28:S13–S18.
   PubMed Web of Science ®Google Scholar
• Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina. 2008;28:831–838.
   PubMed Web of Science ®Google Scholar
• Quiroz-Mercado H, Martinez Castellanos M, Hernandez-Rojas M, et al. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina. 2008;28:S19–S25.
   PubMed Web of Science ®Google Scholar
• Travassos A, Teixeira S, Ferreira P, et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging. 2007;38:233–237.
   PubMedGoogle Scholar
• Kusaka S, Shima C, Wada K, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol. 2008;92:1450–1455.
   PubMed Web of Science ®Google Scholar
• Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J. Ophthalmol. 2012;153:327–333.
   PubMed Web of Science ®Google Scholar
• Yawn BP, Buchanan GR, Afenyi-Annan AN. Management of sickle cell disease: summary of 2013 evidence-based report by expert panel members. JAMA. 2014;312(10):1033–1048.
   PubMed Web of Science ®Google Scholar
• Goldberg MF, Charache S, Acacio I. Ophthalmologic manifestations of sickle cell thalassemia. Arch Intern Med. 1971;128:33–39.
   PubMedGoogle Scholar
• Sayag D, Binaghi M, Souied EH, et al. Retinal photocoagulation for proliferative sickle cell retinopathy: a prospective clinical trial with new sea fan classification. Eur J Ophthalmol. 2008;18(2):248–254.
   PubMed Web of Science ®Google Scholar
• Geeraets WJ, Guerry D. Angioid streaks and sicklecell disease. Am J Ophthal. 1960;49:450–470.
   Google Scholar
• Hoang QV, Chau FY, Shahidi FY. Central macular splaying and outer retinal thinning in asymptomatic sicke cell patients by spectral-domain optical coherence tomography. Am J Ophthalmol. 2011;151(6):990–994.
   PubMed Web of Science ®Google Scholar
• Troumani Y, Caillaux V, Souied EH. Sea fan neovascularization: angiographic and tomographic (SD-OCT) appearance. J Fr Ophthalmolo. 2015;38:665–666.
   PubMed Web of Science ®Google Scholar
• Minvielle W, Caillaux V, Cohen SY, et al. Macular microangiopathy in sicke cell disease using optical coherence tomography angiopathy. Am J Ophtalmol. 2016;164:137–144.
   PubMed Web of Science ®Google Scholar
• Downes SM, Hambleton IR, Chuang EL, et al. Incidence and natural history of proliferative sickle cell retinopathy. Observations from a cohort study. Ophthalmology. 2005;112:1869–1875.
   PubMed Web of Science ®Google Scholar
• Arber MD, Jampol LM, Fox P, et al. A randomized clinical trial of scatter photocoagulation of proliferative sickle cell retinopathy. Arch Ophthalmol. 1991;109:363–367.
   PubMedGoogle Scholar
• MacTel-CNTF Research Group. Chew EY, Clemons TE, Peto T. et al. Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial. Am J Ophthalmol 2015;159(4):659–666.
   PubMed Web of Science ®Google Scholar
• Singer M, Sagong M, van Hemert J, et al. Ultra-widefield imaging of the peripheral retinal vasculature in normal subjects. Ophthalmology. 2016;123(5):1053–1059.
   PubMed Web of Science ®Google Scholar
• Choi W, Moult EM, Waheed NK, et al. Swept source optical coherence tomography angiography in nonexudative age-related macular degeneration with geographic atrophy. Ophthalmology. 2015;122(12):2532–2544.
   PubMed Web of Science ®Google Scholar
• Souied EH, Devin F, Mauget-Faÿsse M, et al. Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. Am J Ophthalmol. 2014;158(4):724–732.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Eliott D, Wells JA, et al. A phase 1 study of intravitreous E10030 in combination with Ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2016;123(1):78–85.
   PubMed Web of Science ®Google Scholar
• Boyer DS, Nguyen QD, Brown DM, et al. Outcomes with as-needed Ranibizumab after initial monthly therapy: long-term outcomes of the phase III RIDE and RISE trials. Ophthalmology. 2015;122(12):2504–2513.
   PubMed Web of Science ®Google Scholar